BioNexus Gene Lab Stock (NASDAQ:BGLC)

Revenue Ownership Financials Chart

Previous Close

$0.30

52W Range

$0.28 - $3.39

50D Avg

$0.39

200D Avg

$0.53

Market Cap

$5.27M

Avg Vol (3M)

$383.11K

Beta

1.87

Div Yield

-

BGLC Company Profile

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

MY

Employees

30

IPO Date

Jan 08, 2021

Website

BGLC Performance

BGLC Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$9.77M	$10.93M	$13.36M
Operating Income	$-2.59M	$-291.18K	$1.06M
Net Income	$-2.63M	$-355.97K	$751.57K
EBITDA	$-2.59M	$-185.76K	$1.16M
Basic EPS	$-0.17	$-0.02	$0.05
Diluted EPS	$-0.17	$-0.02	$0.05

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
OEC	Orion Engineered Carbons S.A.
GEVO	Gevo, Inc.
ALTO	Alto Ingredients, Inc.
PRM	Perimeter Solutions, SA
NEU	NewMarket Corporation
CRKN	Crown ElectroKinetics Corp.
FUL	H.B. Fuller Company
IOSP	Innospec Inc.
LOOP	Loop Industries, Inc.
BCPC	Balchem Corporation
SNES	SenesTech, Inc.